13904 Federal Register / Vol. 62, No. 56 / Monday, March 24, 1997 / Notices

disposition have been met. By separate

action, the NRC has granted in

accordance with 10 CFR 50.12, upon its

own initiative, a specific exemption to

the part of the requirements in 10 CFR

50.82(b)(6)(ii) that requires as a

condition of license termination a

terminal radiation survey and associated

documentation to demonstrate that the

site is suitable for release. Because the

AGN–201 is located in the same room

as the University of Utah TRIGA

Research Reactor (Docket No. 50–407,

Facility Operating License No. R–126),

the Reactor Room in the Merrill

Engineering Building is not being

released for unrestricted use by this

Order and will continue to be subject to

the terms of Operating License No. R–

126 for the TRIGA Research Reactor.

Only residual reactor components from

the AGN–201 remaining on Amended

Facility Operating License No. R–25 are

being released for unrestricted use by

this action.

The terminal radiation survey and

associated documentation demonstrate

that the remaining reactor components

are suitable for release. Confirmatory

radiological surveys verified that the

reactor components meet the

recommended regulatory guidance for

release of the components for

unrestricted use. Accordingly, the

Commission has found that the

decommissioning has been performed in

accordance with the approved

decommissioning plan in that the

reactor has been dismantled and

decontaminated pursuant to the

Commission’s Order dated August 1,

1991. Satisfactory disposition has been

made of the component parts and fuel

in accordance with the Commission’s

regulations in 10 CFR Chapter I, and in

a manner not inimical to the common

defense and security, or to the health

and safety of the public. Therefore, on

the basis of the application filed by the

University of Utah, and pursuant to

Sections 104 and 161 b, and i, of the

Atomic Energy Act of 1954, as amended,

and in accordance with 10 CFR

50.82(b)(6), Amended Facility Operating

License No. R–25 is terminated as of the

date of this Order. In accordance with

10 CFR Part 51, the Commission has

determined that the issuance of this

termination Order will have no

significant environmental impact. The

Environmental Assessment and Finding

of No Significant Impact was published

in the Federal Register on March 13,

1997 (62 FR 11935).

For further details with respect to this

action, see (1) the application for

termination of Amended Facility

Operating License No. R–25, dated July

17, 1990, as supplemented; (2) the

Commission’s safety evaluation related

to the termination of the license; (3) the

environmental assessment and finding

of no significant impact; (4) the

Commission’s exemption to part of the

requirements of 10 CFR 50.82(b)(6); and

(5) the ‘‘Notice of Proposed Issuance of

Orders Authorizing Disposition of

Component Parts and Terminating

Facility License,’’ published in the

Federal Register on May 9, 1991 (56 FR

21508). Each of these items is available

for public inspection at the

Commission’s Public Document Room,

2120 L Street, NW., Washington, D.C.

20037.

Copies of items (2), (3), (4), and (5)

may be obtained upon receipt of a

request addressed to the U.S. Nuclear

Regulatory Commission, Washington,

D.C. 20555–0001, Attention: Director,

Division of Reactor Program

Management.

Dated at Rockville, Maryland, this 14th day

of March 1997.

For the Nuclear Regulatory Commission.

Thomas T. Martin,

Director, Division of Reactor Program

Management Office of Nuclear Reactor

Regulation

[FR Doc. 97–7320 Filed 3–21–97; 8:45 am]

BILLING CODE 7590–01–P

[Docket No. 50–72]

University of Utah (University of Utah

AGN–201 Research Reactor);

Exemption

I

The University of Utah (the licensee)

is the holder of Facility Operating

License Nos. R–25 and R–126, which

authorize operation of the University of

Utah AGN–201 Research Reactor (AGN–

201) and the University of Utah TRIGA

Research Reactor (TRIGA). The licenses

provide, among other things, that the

licensee is subject to all rules,

regulations, and orders of the

Commission now or hereafter in effect.

The reactors are located in the Reactor

Room in the Merrill Engineering

Building on the campus of the

University of Utah in Salt Lake City,

Salt Lake County, Utah.

II

By application dated July 17, 1990, as

supplemented on July 18, 1990, and

June 12, 1991, the licensee requested

from the U.S. Nuclear Regulatory

Commission (NRC or the Commission)

authorization to dismantle and dispose

of the component parts of the AGN–201.

The letter of July 17, 1990, contained a

request that upon successful completion

of decommissioning, authorization be

given for termination of Amended

Facility Operating License No. R–25. By

Order dated August 1, 1991 (56 FR

37733), the Commission authorized

dismantling of the AGN–201 and

disposition of component parts as

proposed in the decommissioning plan

of the licensee. By letter dated April 13,

1994, as supplemented on March 17 and

22, 1995, and February 6, 1996, the

licensee submitted ‘‘A Summary of the

Decommissioning Process of the

University of Utah AGN–201M Reactor

No. 107.’’ As discussed in the

University of Utah’s decommissioning

plan and letter of March 22, 1995, the

site where the AGN–201 is housed is

also under the license of the TRIGA and

is a restricted environment.

As part of the license termination

process, the NRC has decided to grant

upon its own initiative a specific

exemption in accordance with Title 10

of the Code of Federal Regulations,

§ 50.12 (10 CFR 50.12), to part of the

requirements of 10 CFR 50.82(b)(6)(ii).

The part of the regulation for which the

staff is granting an exemption requires,

as a condition of license termination,

that a terminal radiation survey and

associated documentation demonstrates

that the site is suitable for release. The

University of Utah operates the TRIGA

(Docket No. 50–407, Facility Operating

License No. R–126) in the same room

(Reactor Room in the Merrill

Engineering Building) where the AGN–

201 is located. The Reactor Room will

remain subject to the TRIGA license

after termination of the AGN–201

license, and, therefore, a terminal

survey of the site is not necessary for

termination of the AGN–201 license. All

that remains of the AGN–201 are reactor

components that are to be released for

unrestricted use. The Reactor Room will

be considered for release in the future

when the University of Utah requests

termination of the TRIGA license.

III

Pursuant to 10 CFR 50.12, the

Commission may, upon application by

any interested person or upon its own

initiative, grant exemptions from the

requirements of 10 CFR Part 50 when (1)

the exemptions are authorized by law,

will not present an undue risk to public

health or safety, and are consistent with

the common defense and security and

(2) when special circumstances are

present. Special circumstances are

present, according to 10 CFR

50.12(a)(2)(ii), whenever ‘‘application of

the regulation in the particular

circumstances would not serve the

underlying purpose of the rule or is not

necessary to achieve the underlying

purpose of the rule.’’
Federal Register / Vol. 62, No. 56 / Monday, March 24, 1997 / Notices 13905

The underlying purpose of 10 CFR

50.82(b)(6) is to describe the

requirements that must be met for

license termination, one of which is that

the results of the terminal survey and

other documentation show that the

facility and site meet the requirements

for release. These survey results and

documentation form part of the basis for

terminating the license. In this case, the

remaining reactor components (the

facility) will be released, but the site

will not be released. Because the site

will continue to be subject to the NRC

license for the TRIGA reactor,

application of the rule that the terminal

survey and other documentation must

show that the site is suitable for release

is not necessary in order to terminate

the license.

IV

For the foregoing reasons, the NRC

staff has concluded that not requiring a

terminal radiation survey and associated

documentation that demonstrate that

the site is suitable for release as a

condition of license termination will not

present an undue risk to public health

and safety and is consistent with the

common defense and security. The NRC

staff has determined that there are

special circumstances present, as

specified in 10 CFR 50.12(a)(2), in that

application of part of 10 CFR

50.82(b)(6)(ii) is not necessary in order

to achieve the underlying purpose of

this regulation.

Accordingly, the Commission has

determined that, pursuant to 10 CFR

50.12(a), an exemption is authorized by

law, will not endanger life or property

or common defense and security, and is

otherwise in the public interest.

Therefore, the Commission hereby

grants an exemption from the

requirements of 10 CFR 50.82(b)(6)(ii)

that a terminal radiation survey and

associated documentation demonstrates

that the site is suitable for release are

needed as a condition of Operating

License No. R–25 termination.

Pursuant to 10 CFR 51.32, the

Commission has determined that the

granting of this exemption will not have

a significant effect on the quality of the

human environment (62 FR 11936).

For further details with respect to this

action, see (1) the application for

termination of Amended Facility

Operating License No. R–25, dated July

17, 1990, as supplemented; (2) the

Commission’s safety evaluation related

to the termination of the license; (3) the

environmental assessment and finding

of no significant impact; and (4) the

Commission’s Order terminating

Amended Facility Operating License

No. R–25. Each of these items is

available for public inspection at the

Commission’s Public Document Room,

2120 L Street, NW., Washington, D.C.

20037.

Copies of items (2), (3), and (4) may

be obtained upon receipt of a request

addressed to the U.S. Nuclear

Regulatory Commission, Washington,

D.C. 20555–0001, Attention: Director,

Division of Reactor Program

Management.

This exemption is effective upon

issuance.

Dated at Rockville, Maryland, this 14th day

of March 1997.

For the Nuclear Regulatory Commission.

Samuel J. Collins,

Director, Office of Nuclear Reactor

Regulation.

[FR Doc. 97–7338 Filed 3–21–97; 8:45 am]

BILLING CODE 7590–01–P

Nominations of New Members of the

Advisory Committee on the Medical

Uses of Isotopes

AGENCY: U.S. Nuclear Regulatory

Commission

ACTION: Call for nominations.

SUMMARY: The U.S. Nuclear Regulatory

Commission is inviting nominations for

three positions on the Advisory

Committee on the Medical Uses of

Isotopes (ACMUI) to fill current and

upcoming committee vacancies. One

position is for a physician practicing

nuclear cardiology. The second position

is for a patients’ rights and care

advocate. The third position is for an

individual with State or local

government perspective.

DATES: Nominations are due May 23,

1997.

ADDRESSES: Submit nominations to: The

Office of Personnel, Attn: Ms. Jude

Himmelberg, Mail Stop T2D32, U.S.

Nuclear Regulatory Commission,

Washington, DC 20555.

FOR FURTHER INFORMATION CONTACT:

William B. McCarthy, Office of Nuclear

Material Safety and Safeguards, U.S.

Nuclear Regulatory Commission,

Washington, DC 20555, Telephone:

301–415–7894.

SUPPLEMENTARY INFORMATION: The

ACMUI advises NRC on policy and

technical issues that arise in regulating

the medical use of byproduct material

for diagnosis and therapy.

Responsibilities include providing

guidance and comments on changes in

NRC rules, regulations, and guides

concerning medical use; evaluating

certain non-routine uses of byproduct

material for medical use; and providing

technical assistance in licensing,

inspection, and enforcement cases.

Committee members possess the

medical and technical skills needed to

address evolving issues. Currently, the

ACMUI membership consists of: (a)

three practicing physicians; (b) a

physician representing the U.S.

Department of Health and Human

Services, Food and Drug

Administration; (c) a nuclear

pharmacist; (d) two medical physicists

(nuclear medicine and therapy); (e) a

health care administrator; (f) a certified

medical dosimetrist; and (g) a patients’

rights and care advocate (whose term

expires September 30, 1997). Presently,

the specialties of the physicians on the

ACMUI are: therapeutic radiology, with

expertise in teletherapy and

brachytherapy (two), and nuclear

medicine research (one). The staff is in

the process of finalizing the

appointment of a nominee for the

position of nuclear medicine physician.

The U.S. Nuclear Regulatory

Commission is inviting nominations for

three positions on the Advisory

Committee on the Medical Uses of

Isotopes (ACMUI). One position is for a

physician practicing nuclear cardiology.

The second position is for a patients’

rights and care advocate. The third

position is for an individual with State

or local government perspective.

Nominees must include four copies of

their resumes, describing their

educational and professional

qualifications, and provide their current

addresses and telephone numbers.

All new committee members will

serve 3-year terms, with possible

reappointment to an additional 3-year

term.

Nominees must be U.S. citizens and

be able to devote approximately 80

hours per year to committee business.

Members will be compensated and

reimbursed for travel (including per

diem in lieu of subsistence), secretarial,

and correspondence expenses.

Nominees will undergo a security

background check and will be required

to complete financial disclosure

statements, to avoid conflict-of-interest

issues.

Dated at Rockville, Maryland, this 18th day

of March, 1997.

For the U.S. Nuclear Regulatory

Commission.

Andrew L. Bates,

Advisory Committee Management Officer,

Office of the Secretary of the Commission.

[FR Doc. 97–7316 Filed 3–21–97; 8:45 am]

BILLING CODE 7590–01–P